表紙
市場調查報告書
商品編碼
353905

大腸癌症診斷藥·治療藥的全球市場 - 成長·趨勢·預測

Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 113 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

面向本報告彙整全球大腸癌症診斷藥及治療藥的市場相關分析,彙整市場基本結構和最新形勢,主要的推動及阻礙市場要素,市場規模趨勢預測 (今後6年份),模式 (各診斷/治療法) 及地區別詳細趨勢,市場競爭的動向 (各種資本交易等),主要企業的簡介等資訊,為您概述為以下內容。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析

第5章 市場區隔

  • 模式 (手法) 別
    • 診斷法
      • 驗便
      • 免疫組織化學 (IHC)
      • 大腸內視鏡檢驗
      • 軟性S字結腸鏡檢驗
      • 其他診斷法
    • 治療方法
      • 化療
        • 代謝拮抗劑
          • Fluorouracil
          • Capecitabine
        • 烷化劑
          • 奧沙利鉑(Oxaliplatin)
        • 其他
      • 免疫療法
        • Bevacizumab
        • Cetuximab
        • panitumumab
      • 癌症防禦物質
      • 其他
  • 各地區
    • 北美 (美國,加拿大,墨西哥等)
    • 歐洲 (德國,英國,法國,義大利,西班牙等)
    • 亞太地區 (中國,日本,印度,澳洲,韓國等)
    • 中東·非洲 (波灣合作理事會 (GCC) 各國,南非等)
    • 南美 (巴西,阿根廷等)

第6章 競爭環境

  • 企業簡介
    • Abbott Laboratories
    • Amgen Inc.
    • Clinical Genomics
    • EDP Biotech
    • Epigenomics AG
    • F. Hoffmann-La Roche AG
    • Novigenix SA
    • Quest Diagnostics
    • Sanofi SA
    • Siemens Healthineers
    • VolitionRX

第7章 市場機會及未來趨勢

目錄
Product Code: 50590

The colorectal cancer diagnostics and therapeutics market is expected to register a CAGR of nearly 4.6% during the forecast period.

Key Highlights

  • Colorectal cancer has one of the largest incidence and prevalence rates, worldwide. Primary causes of colorectal cancer are said to be lifestyle disorders, ageing, and diet.
  • According to the World Health Organization (WHO), an increase of around 70% is expected in the colorectal cancer cases across the world, by 2030.
  • Therefore, high incidence and prevalence rates are the primary factors, driving the market studied.
  • According to a research article published in 2016, "Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the United States".
  • Colorectal cancer (CRC) is estimated to account for over 9% of all cancer incidences and is a major cause of morbidity and mortality throughout the world. CRC is the second-most-common cause of cancer-related deaths in the United States.

Key Market Trends

Immunotherapy Expected to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.

  • Immunotherapy refers to the fighting cancer cells by taking advantage of the human immune system. There are several immunotherapy drugs available for colorectal cancer worldwide. These therapeutics include targeted antibodies and checkpoint inhibitors.
  • s.Furthermore, growing R&D on combination therapy coupled with rising awareness on cancer therapeutics and advantages of immunotherapy anticipated fueling the segment growth over the forecast period.
  • For instance, In August 2018, United States Food and Drug Administration approved combination of immunotherapeutic drugs ipilimumab (Yervoy) and nivolumab (Opdivo) for the treatment of some patients with metastatic colorectal cancer who have been treated previously with standard chemotherapy drugs.
  • Moreover, the expansion of therapeutic applications of immunotherapeutic agents to colorectal cancer is projected to further fuel the market growth.

United States is Expected to Retain Largest Market Share During the Forecast Period

  • Geographically, the North Americacolorectal cancer diagnostics and therapeutics market projected to have significant market share with respect to demand and revenue.
  • In 2017, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States based on the estimates by the American Cancer Society. These estimates indicate that colorectal cancer is increasing its prevalence in the United States, which is in turn, leading to the growth of the market.
  • Moreover, the Asia-Pacific colorectal cancer diagnostics and therapeutics market is also expected to witness a strong growth pattern in the coming years, with China and India showing rapid progress.
  • For instance, Chi-Med's Fruquintinob ha got approved for the treatment of colorectal cancer in China. This is expected to increase access to colorectal cancer therapeutics in China.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global colorectal cancer diagnostic and therapeutics market. Moreover, several new biotech firms are also active in the therapeutics by launching new products participating in collaborations and acquisitions. Key players in the market include Abbott Laboratories, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, and Siemens Healthineers among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Radiology and Chemotherapy
    • 4.2.2 Increasing Incidence and Prevalence of Colorectal Cancer
  • 4.3 Market Restraints
    • 4.3.1 High Costs and the Side Effects Associated with Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Modality
    • 5.1.1 Diagnostics Techniques
      • 5.1.1.1 Stool Tests
      • 5.1.1.2 Immunohistochemistry
      • 5.1.1.3 Colonoscopy
      • 5.1.1.4 Flexible Sigmoidoscopy
      • 5.1.1.5 Other Diagnostics Techniques
    • 5.1.2 Therapeutics
      • 5.1.2.1 Chemotherapy
      • 5.1.2.2 Immunotherapy
      • 5.1.2.3 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Amgen Inc.
    • 6.1.3 Clinical Genomics
    • 6.1.4 EDP Biotech
    • 6.1.5 Epigenomics AG
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Novigenix SA
    • 6.1.8 Quest Diagnostics
    • 6.1.9 Sanofi SA
    • 6.1.10 Siemens Healthineers
    • 6.1.11 VolitionRX

7 MARKET OPPORTUNITIES AND FUTURE TRENDS